Apolipoprotein B Monoclonal Antibody (F2C9), Invitrogen™

Description

• MIA1609 targets Apolipoprotein B in ELISA, IP and RIA applications and shows reactivity with Human samples
• The MIA1609 immunogen is purified human serum LDL
• MIA1609 detects Apolipoprotein B which has a predicted molecular weight of approximately 502 kDa
• MIA1609 was formerly sold as a Seradyn product
• Apolipoprotein B (apo B) in human plasma is a major protein of low density lipoproteins (LDL) with a molecular mass of approximately 260-500 kDa
• Apolipoprotein B binds to specific receptors on cell membranes and is involved in removal of LDL and very low density lipoprotein (VLDL) cholesterol from circulation
• Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood
• LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation
• In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36
• Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described
• MDA-oxidized LDL appear to be different from LDL oxidized by other means
• Apolipoprotein B is mostly synthesized in the liver, and is a major apolipoprotein of very low density, intermediate density and low density lipoproteins (LDL) as well as being a major component of lipoprotein (a)
• Apolipoprotein B is a ligand for the LDL receptor and elevated levels are associated with premature atherosclerosis
• Normal plasma apolipoprotein B levels are around 800mg/L
• Apolipoprotein B occurs in plasma as two main isoforms, apoB-48 and apoB-100
• The intestinal and the hepatic forms of Apolipoprotein B are encoded by a single gene from a single, very long mRNA
• The two isoforms share a common N-terminal sequence
• The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination
• Mutations in the Apolipoprotein B gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective Apolipoprotein B, diseases affecting plasma cholesterol and Apolipoprotein B levels.